Last reviewed · How we verify
NCT05032209: S2AEA
Follow-up of Children With Severe Asthma at Adult Age
trial testing follow-up of children with severe asthma in adulthood in Severe Asthma in 60 participants. Status unknown.
12 July 2022
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 12 July 2021 |
| Primary completion | 12 July 2022 |
| Estimated completion | 12 July 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- follow-up of children with severe asthma in adulthood
Conditions studied
- Severe Asthma — all drugs for Severe Asthma →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
18 and older, any sex, with Severe Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Most of clinical cohorts focused on the course of asthma over time and on the different phenotypes of asthma have investigated children and adults separately. The passage from childhood to adulthood is scarcely explored. In this context, we decided to explore the course of asthma severity from teenage to adulthood in children with severe asthma. The secondary objectives are to assess the quality of life and socioeconomic status in adulthood. This study will be both retrospective (data collected during childhood) and prospective (data collected during adulthood), multicentric and observational
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05032209
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Severe Asthma
Currently open trials in the same condition.
- NCT07363642 — Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab · Phase 3 · recruiting
- NCT07328035 — Remission in Adults With Severe Asthma in Thailand · recruiting
- NCT07530770 — Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis · recruiting
- NCT06903780 — Experience of Biologic Treatments for Severe Asthma: a Survey · recruiting
- NCT06681545 — Exploring the Lived Experience of Young Adults With Severe Asthma · recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05032209 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 2 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05032209.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing